State of Art of Anti-HIV/AIDS Vaccine Clinical Trials based on the recombinant biologically active HIV-1 Tat protein sponsored by ISS updated on november 26th 2013.
Please be advised that we cannot provide any medical information (about drugs, treatments, diagnostics, etc.). You are kindly requested to refer to your doctor or to Telefono Verde AIDS at the Istituto Superiore di Sanità (toll free number from Italy 800 861 061).
Our aim is fighting HIV/AIDS and associated syndromes by developing vaccines and new therapeutic approaches based on studies of the pathogenic mechanisms of HIV infection and progression. The NAC organization reflects the aim to put into effect a “translational” research.
The Tat-based phase II clinical trial “ISS T-002”.
Barbara Ensoli, Director of the National AIDS Center- ISS, was appointed among the new members of the European Research Council (European Research Council,...
© - Istituto Superiore di Sanità Viale Regina Elena 299 - 00161 - Roma (I)
Partita I.V.A. 03657731000 - C.F. 80211730587 - Legal information